ALV003 placebo

BIOLOGICAL2 trials

Sponsors

Alvine Pharmaceuticals Inc.

Conditions

Celiac Disease

Phase 2

Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

CompletedNCT00959114

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2009-08-31End: 2010-10-31Updated: 2012-08-06

Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease

CompletedNCT01255696

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2010-11-30End: 2011-06-30Updated: 2012-08-06

Related Papers

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.

2014-02-25165 citations